MYRIAD GENETICS, INC. (MYGN) Return on equity 2016–2025
MYRIAD GENETICS, INC. (MYGN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-99.4%FY2025 · since FY2016: 2.3% → -99.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -99.4% | -81.3 pp |
| FY2024 | -18.2% | +15.5 pp |
| FY2023 | -33.6% | -21.0 pp |
| FY2022 | -12.6% | -9.8 pp |
| FY2021 | -2.8% | +22.6 pp |
| FY2020 | -25.4% | -3.7 pp |
| FY2019 | -21.7% | -22.1 pp |
| FY2018 | 0.4% | -13.4 pp |
| FY2017 | 13.8% | +11.5 pp |
| FY2016 | 2.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More MYGN financial trends
MYGN RevenueMYGN Net incomeMYGN Net marginMYGN Gross profitMYGN Gross marginMYGN Operating incomeMYGN Operating marginMYGN Operating cash flowMYGN Free cash flowMYGN Capital expendituresMYGN Stock buybacksMYGN Dividends paidMYGN Total assetsMYGN Total liabilitiesMYGN Shareholders’ equityMYGN overview →